Trump Charges FDA to Streamline Prescription Drug Importation Program
An April 15 executive order from President Donald Trump calls for examining the impact of importing higher volumes of prescription drugs to lower prescription drug costs in the U.S.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
The order, "Lowering Drug Prices By Once Again Putting Americans First," charges the Department of Health and Human Services via the FDA to "streamline and improve" the importation program under Section 804 of the Federal Food, Drug and Cosmetic Act to make it easier for U.S. states to obtain approval to dispense imported prescription drugs "without sacrificing safety or quality."
The intent of this action is to increase prescription drug importation to lower prices, according to a heading in the executive order, which lays out additional non-import-related actions addressing drug costs.
The order gives the FDA commissioner a deadline of 90 days to complete this process.